Wedge Capital Management L L P NC Purchases 8,063 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Wedge Capital Management L L P NC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,775 shares of the biopharmaceutical company’s stock after buying an additional 8,063 shares during the period. Wedge Capital Management L L P NC’s holdings in Regeneron Pharmaceuticals were worth $29,790,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its position in Regeneron Pharmaceuticals by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock worth $7,004,838,000 after acquiring an additional 26,884 shares during the last quarter. Dodge & Cox raised its holdings in shares of Regeneron Pharmaceuticals by 1.0% in the fourth quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock valued at $3,547,791,000 after purchasing an additional 45,513 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Regeneron Pharmaceuticals by 4.4% in the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock worth $1,975,990,000 after purchasing an additional 106,861 shares in the last quarter. Nuveen LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after purchasing an additional 835,240 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Regeneron Pharmaceuticals by 142.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after purchasing an additional 1,144,887 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on REGN shares. Barclays decreased their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. TD Cowen raised their price objective on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. HSBC lowered their target price on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. JPMorgan Chase & Co. decreased their price target on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research note on Monday, May 18th. Finally, Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $797.75.

Regeneron Pharmaceuticals Trading Down 1.4%

Shares of Regeneron Pharmaceuticals stock opened at $797.00 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The company has a market capitalization of $82.06 billion, a price-to-earnings ratio of 19.70, a P/E/G ratio of 1.37 and a beta of 0.22. The business has a fifty day simple moving average of $665.31 and a two-hundred day simple moving average of $713.04. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $12.81 EPS. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is 9.29%.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Goldman Sachs maintained its Buy rating on Regeneron, signaling continued confidence in the company’s business and pipeline prospects. Goldman Sachs Keeps Their Buy Rating on Regeneron
• Positive Sentiment: Recent analysis highlighted continued strength in Eylea HD and Dupixent, along with oncology growth and pipeline progress. The stock has risen 21.9% over the past month, although the sharp advance may also increase profit-taking risk. REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
• Neutral Sentiment: The reported short-interest data shows zero shares sold short and a zero-day short-interest ratio, but the figures also contain an undefined percentage change and appear unreliable. Consequently, the data provides no meaningful indication of short-covering or bearish positioning.
• Negative Sentiment: Several law firms, including Pomerantz, Gross, Faruqi & Faruqi, and Hagens Berman, are promoting or reminding investors about a securities class action against Regeneron. The litigation follows disclosures that a Phase 3 melanoma therapy trial failed, an event reportedly associated with an approximately $11 billion market-capitalization loss. The legal notices themselves do not establish wrongdoing, but they add reputational and potential financial-risk concerns. Investors covered by the proposed class period may face a September 14, 2026 lead-plaintiff deadline. REGN Investor Alert

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.